Announced Date: 2023-05-09 (May 9, 2023) Asset Name: ZN-A-1041 (RG6596, perzebertinib) Licensor (Seller): Zion Pharma (China) … [China BD 2023] Zion Pharma and Roche enters a 680 million USD acquisition on HER2 TKI ZN-A-1041 (RG6596)Read more
[China BD 2023] DualityBio and BioNTech enters a 1.67 billion USD license on two ADC Assets, HER2 ADC DB-1303 (BNT323) and B7-H3 ADC DB-1311 (BNT324)
Announced Date: 2023-04-03 (April 3, 2023) Asset Name: DB-1303(BNT323)，DB-1311(BNT324) Licensor: Duality Biologics (Suzhou) (DualityBio, China) Licensee … [China BD 2023] DualityBio and BioNTech enters a 1.67 billion USD license on two ADC Assets, HER2 ADC DB-1303 (BNT323) and B7-H3 ADC DB-1311 (BNT324)Read more
[China BD 2023] Highlightll and Biohaven enters a 970 million USD License on Dual TYK2/JAK1 Inhibitor TLL-041 (BHV-8000)
Announced Date: 2023-03-22 March 22, 2023) Asset Name: TLL-041 (BHV-8000) Licensor (Seller): Hangzhou Highlightll Pharmaceutica (China) … [China BD 2023] Highlightll and Biohaven enters a 970 million USD License on Dual TYK2/JAK1 Inhibitor TLL-041 (BHV-8000)Read more
[China BD 2023] KYM Biosciences (Keymed / Lepu) and AstraZeneca Enters License on Claudin-18.2 ADC CMG901
Announced Date: 2023-02-23 (February 23, 2023) Asset Name: CMG901 Licensor (Seller): KYM Biosciences (China) (joint venture … [China BD 2023] KYM Biosciences (Keymed / Lepu) and AstraZeneca Enters License on Claudin-18.2 ADC CMG901Read more
[China BD 2023] Hengrui and Treeline enters a 706 million USD license on EZH2 inhibitor SHR2554 (TLN-254)
Announced Date: 2023-02-12 (February 12, 2023) Asset Name: SHR2554 (TLN-254) Licensor: Hengrui Pharmaceuticals Co. Ltd (China) … [China BD 2023] Hengrui and Treeline enters a 706 million USD license on EZH2 inhibitor SHR2554 (TLN-254)Read more
[China BD 2023] Zhimeng Biopharma and GSK enters a license on TLR8A CB06-036 (CB06) for HBV treatment
Announced Date: 2023-02-01 (February 1, 2023) Asset Name: CB06-036（CB06） Licensor: Shanghai Zhimeng Biopharma (China) Licensee (Buyer): … [China BD 2023] Zhimeng Biopharma and GSK enters a license on TLR8A CB06-036 (CB06) for HBV treatmentRead more
[China BD 2023] HutchMed and Takeda enters a 1.13 billion USD License on VEGFR TKI Fruquintinib
Announced Date: 2023-01-23 (January 23, 2023) Asset Name: Fruquintinib Licensor: HutchMed (China) Licensee (Buyer): Takeda (Japan) … [China BD 2023] HutchMed and Takeda enters a 1.13 billion USD License on VEGFR TKI FruquintinibRead more
[China BD deal 2022] Kelun-Biotech and Merck/MSD enters a 9.5 billion USD license on seven preclinical ADCs
Announced Date: 2022-12-22 (December 22, 2022) Asset: Seven investigational preclinical ADC for the treatment of cancer. … [China BD deal 2022] Kelun-Biotech and Merck/MSD enters a 9.5 billion USD license on seven preclinical ADCsRead more
[China BD 2022] Akeso and Summit Enters a 5 billion USD License on PD-1/VEGF BsAbs Ivonescimab (AK112 / SMT112)
Announced Date: 2022-12-06 (December 06, 2022) Asset Name: Ivonescimab (AK112, SMT112) Licensor: Akeso Inc. (China) Licensee … [China BD 2022] Akeso and Summit Enters a 5 billion USD License on PD-1/VEGF BsAbs Ivonescimab (AK112 / SMT112)Read more
[China FIC Drug] Global First In Class Glucokinase Activator Dorzagliatin (Oral Antidiabetic Drug) Approved by China NMPA in 2022
Drug Name: Dorzagliatin Drug Modality: Small Molecule Drug Target: GKA (Glucokinase Activator ) Developed By：Hua Medicine Approved Date: … [China FIC Drug] Global First In Class Glucokinase Activator Dorzagliatin (Oral Antidiabetic Drug) Approved by China NMPA in 2022Read more